ASCO GU 2022 - Results from #260

Viewing 261-280 of 316 articles

ASCO GU 2022: The Effect of Postoperative Pathological Findings Related to the Eligibility of Adjuvant Immunotherapy on Oncologic Outcomes in Patients With Locally Advanced Urothelial Cancer

ASCO GU 2022: Clinical Utility of Next-Generation Sequencing for Prostate Cancer in the Context of a Changing Treatment Landscape

ASCO GU 2022: Evaluation of Drug-Drug Interactions Among Patients With Metastatic Prostate Cancer in Routine Care

ASCO GU 2022: Enzalutamide Versus Abiraterone Plus Prednisolone Before Chemotherapy for Japanese Castration-Resistant Prostate Cancer Patients: An Investigator-Initiated, Multicenter, Randomized Controlled Trial

ASCO GU 2022: Patterns of Progression of Patients With High-Volume Metastatic Castration-Sensitive Prostate Cancer Treated With Early Docetaxel Chemotherapy: The LONGITUDE Observational Study

ASCO GU 2022: A Randomized, Double-Blind, Placebo-Controlled, Phase 3b Study of the Efficacy and Safety of Continuing ENZA in Chemotherapy-Naïve, mCRPC Patients Treated with Docetaxel Plus Prednisolone Who have Progressed on ENZA

ASCO GU 2022: Safety and Preliminary Clinical Activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 Bispecific Antibody, for the Treatment of Metastatic Castrate-Resistant Prostate Cancer

ASCO GU 2022: A Phase II Trial of Abemaciclib and Atezolizumab in Unselected and CDK12-Loss Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022: The Role of Sabizabulin in Phase 1b/2 Clinical Trials of Men With Metastatic Castration-Resistant Prostate Cancer Who Progressed on Androgen Receptor-Targeting Agents

ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2022: Veterans Affairs Seamless Phase II/III Randomized Trial of Standard Systemic Therapy with or Without PET-Directed Local Therapy for Oligorecurrent Prostate Cancer (VA STARPORT)

ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)

ASCO GU 2022: Updated Overall Survival (OS) Analysis for ProCAID: A Randomized, Double Blind, Placebo-Controlled Phase II Trial of Capivasertib with Docetaxel Versus Docetaxel Alone in Metastatic Castration Resistant Prostate Cancer (mCRPC)

ASCO GU 2022: Hereditary Cancer Risk Assessment in the Community Urology Practice Setting

ASCO GU 2022: Phase 3 MAGNITUDE Study: First Results of Niraparib With Abiraterone Acetate and Prednisone As First-Line Therapy in Patients With mCRPC With and Without HRR Gene Alterations

ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with mCRPC

ASCO GU 2022: Targeting Prostate-Specific Membrane Antigen: Lutetium and the Next Wave of Novel Radiopharmaceuticals

ASCO GU 2022: Active Surveillance for Patients with Intermediate-Risk Disease: Risk Versus Benefit

ASCO GU 2022: Impact of AR-V7 and Other Androgen Receptor Splice Variant Expression on Outcomes of Post-Prostatectomy Salvage Therapy

ASCO GU 2022: Phase I/II Trial of Pembrolizumab and AR Signaling Inhibitor +/- 225Ac-J591 for Chemo-Naive Metastatic Castration-Resistant Prostate Cancer

7
8
9
10
11
12
13
14
15
16